Compounds > levofloxacin

Page last updated: 2024-09-04

levofloxacin and papaverine

levofloxacin has been researched along with papaverine in 8 studies

Compound Research Comparison

Studies (levofloxacin)	Trials (levofloxacin)	Recent Studies (post-2010) (levofloxacin)	Studies (papaverine)	Trials (papaverine)	Recent Studies (post-2010) (papaverine)
4,346	581	2,209	6,027	305	355

Protein Interaction Comparison

Protein	Taxonomy	levofloxacin (IC50)	papaverine (IC50)
Chain A, cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Rattus norvegicus (Norway rat)		0.076
cGMP-dependent 3',5'-cyclic phosphodiesterase	Homo sapiens (human)		2.3
cGMP-specific 3',5'-cyclic phosphodiesterase	Homo sapiens (human)		8.8
3',5'-cyclic-AMP phosphodiesterase	Sus scrofa (pig)		1.7
Bile salt export pump	Homo sapiens (human)		10
cAMP-specific 3',5'-cyclic phosphodiesterase 4A	Homo sapiens (human)		1.6
Cytochrome P450 2C19	Homo sapiens (human)		0.762
Serine hydroxymethyltransferase, mitochondrial	Homo sapiens (human)		2.6915
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Homo sapiens (human)		9
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Homo sapiens (human)		9
cAMP-specific 3',5'-cyclic phosphodiesterase 4D	Homo sapiens (human)		1.4
Potassium voltage-gated channel subfamily H member 2	Homo sapiens (human)		7.2444
cGMP-inhibited 3',5'-cyclic phosphodiesterase B	Homo sapiens (human)		1.03
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C	Homo sapiens (human)		9
cGMP-inhibited 3',5'-cyclic phosphodiesterase A	Homo sapiens (human)		0.697
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Rattus norvegicus (Norway rat)		0.036
Phosphodiesterase	Sus scrofa (pig)		0.62
cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A	Homo sapiens (human)		0.07

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (25.00)	29.6817
2010's	5 (62.50)	24.3611
2020's	1 (12.50)	2.80

Authors

Authors	Studies
Lombardo, F; Obach, RS; Waters, NJ	1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Gozalbes, R; Pineda-Lucena, A	1
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Auriola, S; Bahrpeyma, S; Del Amo, EM; Hellinen, L; Reinisalo, M; Urtti, A	1

Reviews

1 review(s) available for levofloxacin and papaverine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Other Studies

7 other study(ies) available for levofloxacin and papaverine

Article	Year
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical determinants of human renal clearance. Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15 Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight	2009
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
QSAR-based solubility model for drug-like compounds. Bioorganic & medicinal chemistry, 2010, Oct-01, Volume: 18, Issue:19 Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water	2010
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification. Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Mechanisms of cellular retention of melanin bound drugs: Experiments and computational modeling. Journal of controlled release : official journal of the Controlled Release Society, 2022, Volume: 348 Topics: Animals; Computer Simulation; Levofloxacin; Melanins; Papaverine; Retinal Pigment Epithelium; Swine; Timolol	2022